[go: up one dir, main page]

WO2006060192A3 - Derives de pyrazole - Google Patents

Derives de pyrazole Download PDF

Info

Publication number
WO2006060192A3
WO2006060192A3 PCT/US2005/041903 US2005041903W WO2006060192A3 WO 2006060192 A3 WO2006060192 A3 WO 2006060192A3 US 2005041903 W US2005041903 W US 2005041903W WO 2006060192 A3 WO2006060192 A3 WO 2006060192A3
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazole derivatives
modulation
useful
relates
treating diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/041903
Other languages
English (en)
Other versions
WO2006060192A2 (fr
Inventor
Zahra Fathi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharmaceuticals Corp
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of WO2006060192A2 publication Critical patent/WO2006060192A2/fr
Anticipated expiration legal-status Critical
Publication of WO2006060192A3 publication Critical patent/WO2006060192A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des dérivés de pyrazole utiles dans le traitement de maladies liées à la modulation des récepteurs cannabinoïdes.
PCT/US2005/041903 2004-11-30 2005-11-18 Derives de pyrazole Ceased WO2006060192A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63201104P 2004-11-30 2004-11-30
US60/632,011 2004-11-30

Publications (2)

Publication Number Publication Date
WO2006060192A2 WO2006060192A2 (fr) 2006-06-08
WO2006060192A3 true WO2006060192A3 (fr) 2007-05-31

Family

ID=36565531

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/041903 Ceased WO2006060192A2 (fr) 2004-11-30 2005-11-18 Derives de pyrazole

Country Status (1)

Country Link
WO (1) WO2006060192A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11155521B2 (en) 2012-11-13 2021-10-26 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
IN2015DN03733A (fr) 2012-11-13 2015-09-18 Us Health
US10329259B2 (en) 2014-05-09 2019-06-25 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Pyrazole derivatives and their use as cannabinoid receptor mediators
NL2018504B1 (en) * 2017-03-13 2018-09-21 Pharma Unlimited B V Tobacco- and smoke-less products consumable by humans as epicurean or medical products and method of treating smoking addiction

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
US6344474B1 (en) * 1997-01-28 2002-02-05 Sanofi-Synthelabo Use of central cannabinoid receptor antagonists for regulating appetence
US6476060B2 (en) * 2000-03-23 2002-11-05 Solvay Pharmaceuticals, B.V. 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US6642258B1 (en) * 1999-10-01 2003-11-04 Sanofi-Synthelabo Use of central cannabinoid receptor antagonist for preparing medicines
US20060128673A1 (en) * 2004-10-25 2006-06-15 Michael Firnges Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions
US7109216B2 (en) * 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6344474B1 (en) * 1997-01-28 2002-02-05 Sanofi-Synthelabo Use of central cannabinoid receptor antagonists for regulating appetence
US5939429A (en) * 1997-09-30 1999-08-17 Virginia Commonwealth University Cardiovascular uses of cannabinoid compounds
US6642258B1 (en) * 1999-10-01 2003-11-04 Sanofi-Synthelabo Use of central cannabinoid receptor antagonist for preparing medicines
US6476060B2 (en) * 2000-03-23 2002-11-05 Solvay Pharmaceuticals, B.V. 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
US7109216B2 (en) * 2001-09-21 2006-09-19 Solvay Pharmaceuticals B.V. 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
US20060128673A1 (en) * 2004-10-25 2006-06-15 Michael Firnges Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions

Also Published As

Publication number Publication date
WO2006060192A2 (fr) 2006-06-08

Similar Documents

Publication Publication Date Title
WO2005097825A3 (fr) Variants de bmp-7 ayant des proprietes ameliorees
WO2005062916A3 (fr) Methodes permettant de generer des molecules multimeres
WO2007076070A3 (fr) Modulateurs de recepteurs muscariniques
WO2005000820A3 (fr) Derives de 4-cyanopyrazole-3-carboxamide, leur preparation et leur application comme antagonistes des recepteurs aux cannabinoides cb1
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2006113919A3 (fr) Preparation et utilisation de derives de l'acide aryle alkyle dans le traitement de l'obesite
WO2008133722A3 (fr) Anticorps et diagnostics
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2008005908A3 (fr) Dérivés de pyridoïmidazole
WO2007150015A3 (fr) Procédé de traitement
WO2007020502A3 (fr) Ligands des recepteurs de cannabinoide et utilisations de ceux-ci
WO2007021937A3 (fr) Derives heterocycliques insatures
WO2009071689A3 (fr) Dérivés d'oxindole substitués par halogène en position 5 et leur utilisation pour traiter des maladies liées à la vasopressine
WO2005030188A3 (fr) Derives de phenyl-piperazine en tant que modulateurs des recepteurs muscariniques
WO2006023852A3 (fr) Modulateurs des recepteurs muscariniques
IL191936A0 (en) 4,5-dihydro-(1h)-pyrazole derivatives as cannabinoid cb1 receptor modulators
WO2006058294A3 (fr) Modulateurs des recepteurs muscariniques
IL190278A0 (en) Tetrahydro-cyclopentyl pyrazole cannabinoid modulators
IL188388A0 (en) Pyrazole derivatives as cb1 modulators
WO2007022947A3 (fr) Composes 5-cycle-heteroaromates et leur utilisation en tant que partenaires de liaison des recepteurs 5-ht5
WO2005103010A3 (fr) Composes chimiques
WO2006060192A3 (fr) Derives de pyrazole
WO2005018627A8 (fr) Derives d'alpha-aminoamide utilisables comme agents anti-inflammatoires
WO2006135694A3 (fr) Composes modulateurs d'uii et utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05851838

Country of ref document: EP

Kind code of ref document: A2